The estimated Net Worth of Lawrence J. Hineline is at least $11.9 Million dollars as of 6 March 2024. Mr. Hineline owns over 13,132 units of Intra-Cellular Therapies Inc stock worth over $981,223 and over the last 10 years he sold ITCI stock worth over $8,741,317. In addition, he makes $2,193,530 as Chief Financial Officer, Senior Vice President - Finance, Treasurer, and Assistant Secretary at Intra-Cellular Therapies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Hineline ITCI stock SEC Form 4 insiders trading
Lawrence has made over 31 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 23,253 units of ITCI stock worth $1,542,139 on 7 March 2024.
The largest trade he's ever made was exercising 175,000 units of Intra-Cellular Therapies Inc stock on 21 December 2021 worth over $2,941,750. On average, Lawrence trades about 20,602 units every 79 days since 2014. As of 6 March 2024 he still owns at least 13,132 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Mr. Hineline stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lawrence Hineline biography
Lawrence J. Hineline serves as Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary of the Company. Mr. Hineline has served as Senior Vice President of Finance of the Company since January 2019 and Chief Financial Officer and Treasurer of the Company since the Merger in August 2013. He also served as Vice President of Finance of the Company from the Merger in August 2013 to December 2018. He has served as Vice President of Finance, Chief Financial Officer and Secretary of ITI since June 2002. Mr. Hineline also served as the Secretary of the Company from August 2013 until September 2014. From December 2000 to November 2003, Mr. Hineline was the Vice President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a start-up and was later acquired by Baxter Health Care. Mr. Hineline is a licensed CPA in the State of Maryland and received his Bachelor’s Degree from the University of Maryland Baltimore County.
What is the salary of Lawrence Hineline?
As the Chief Financial Officer, Senior Vice President - Finance, Treasurer, and Assistant Secretary of Intra-Cellular Therapies Inc, the total compensation of Lawrence Hineline at Intra-Cellular Therapies Inc is $2,193,530. There are 3 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.
How old is Lawrence Hineline?
Lawrence Hineline is 63, he's been the Chief Financial Officer, Senior Vice President - Finance, Treasurer, and Assistant Secretary of Intra-Cellular Therapies Inc since 2019. There are 7 older and 9 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.
What's Lawrence Hineline's mailing address?
Lawrence's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus, and Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Mr. Hineline stock trades at Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO